Madison

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Multiple myeloma5 trials
• Colorectal cancer2 trials
• Liver and biliary tract cancer2 trials
• Melanoma2 trials
• Childhood cancers1 trial
• Glioblastoma1 trial
• Hodgkin lymphoma1 trial
• Lung cancer1 trial
• Pancreatic cancer1 trial
• Sarcoma1 trial

Phase

• Phase 1/25 trials
• Phase 12 trials
• Phase 21 trial

Status

• Active, not recruiting6 trials
• Completed1 trial
• Recruiting1 trial

Lead sponsor

• GlaxoSmithKline7 trials
• Tesaro, Inc.1 trial

Running trials

• Recruiting

  A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

  NCT06885034· Phase 1/2· GlaxoSmithKline· Source

  Contact: Dustin Deming (principal investigator)

• Active, not recruiting

  A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

  NCT06521567· Phase 1/2· GlaxoSmithKline· Source

• Active, not recruiting

  Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM

  NCT07217184· Phase 1/2· GlaxoSmithKline· Source

• Active, not recruiting

  Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

  NCT04091126· Phase 1· GlaxoSmithKline· Source

• Active, not recruiting

  Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM

  NCT07217119· Phase 1/2· GlaxoSmithKline· Source

• Active, not recruiting

  Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT04126200· Phase 1/2· GlaxoSmithKline· Source

• Active, not recruiting

  A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

  NCT02817633· Phase 1· Tesaro, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer1 recruiting
• Pancreatic cancer1 recruiting

Closed trials

• Completed

  A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

  NCT03525678· Phase 2· GlaxoSmithKline· Source